You are here: Industry Insights > ALS

News List

Post-Hoc Study Analysis Examines Early Intervention with Edaravone for ALS Survival americanpharmaceuticalreview
March 25, 2021
Mitsubishi Tanabe Pharma America announced a post-hoc analysis of its Phase 3 edaravone study reviewing the results of intravenous (IV) edaravone treatment on disease progression milestones and events among people with amyotrophic lateral sclerosis (ALS).
NeuroSense Reports Positive Results in ALS Study, Patent Allowance for PrimeC americanpharmaceuticalreview
March 08, 2021
NeuroSense Therapeutics has announced the successful completion of its first Phase IIa study. The study, NST002, aimed at establishing various safety endpoints for the company's first drug candidate PrimeC in 15 ALS patients, over a 12-month period.
BrainStorm Receives FDA Feedback on ALS Clinical Development Program americanpharmaceuticalreview
February 25, 2021
BrainStorm Cell Therapeutics recently met with senior leadership from the U.S. Food and Drug Administration (FDA) and received FDA feedback on a high-level data summary from the NurOwn (autologous MSC-NTF cells) ALS Phase 3 clinical trial.
Spinogenix Announces Grant by DOD to Advance ALS Drug Candidate americanpharmaceuticalreview
January 12, 2021
Spinogenix will be collaborating with Dr. Rita Sattler at the Barrow Neurological Institute and Dr. Justin Ichida at the USC Keck School of Medicine on a grant awarded from the U.S. Department of Defense’s (DOD) ...
MTPA Announces Initiation of Open-Label Extension Study of Oral Edaravone in ALS americanpharmaceuticalreview
January 08, 2021
Mitsubishi Tanabe Pharma America (MTPA) announced the initiation of a long-term safety extension study (MT-1186-A03) to the ongoing Phase 3 trial evaluating an investigational oral formulation of edaravone in patients with amyotrophic lateral sclerosis.
BrainStorm Announces NurOwn Expanded Access Program americanpharmaceuticalreview
January 05, 2021
BrainStorm Cell Therapeutics has announced the initiation of a NurOwn® (MSC-NTF cells) Expanded Access Program (EAP) for patients with amyotrophic lateral sclerosis (ALS) who completed the Company's recently concluded pivotal Phase 3 clinical trial ...
AstroRx® shows promise in early phase amyotrophic lateral sclerosis trial europeanpharmaceuticalreview
December 17, 2020
Amyotrophic lateral sclerosis (ALS) patients treated with AstroRx® had a 45 percent reduction in their disease progression rate.
BMS collaborates with insitro to develop drugs for ALS pharmatimes
October 30, 2020
Bristol Myers Squibb has signed a five-year collaboration agreement with machine learning specialist insitro to develop drugs for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.
Ionis Begins ALS Clinical Trial americanpharmaceuticalreview
October 28, 2020
Ionis Pharmaceuticals announced the first patients have been dosed with ION541 (also known as BIIB105), an investigational antisense medicine being developed as a potential therapy to treat most forms of amyotrophic lateral sclerosis (ALS) regardless ...
Catalent, BrainStorm Enter ALS Drug Manufacturing Pact contractpharma
October 23, 2020
Catalent will undertake the transfer of the manufacturing process to, and provide future cGMP clinical supply of NurOwn from its Houston facility.

Previous page 1 2 3 4 5 6 7 8 Next page